Reimbursement, Sales Critical For IPOs As Markets Reopen To Device Firms
This article was originally published in The Gray Sheet
Executive Summary
"Reimbursement clarity" is essential for device firms in gaining investor confidence in the public equity market, Jeffrey Hoffman, health technology investment banker with U.S. Bancorp Piper Jaffray, emphasized at the recent Frost & Sullivan 5th Annual Medical Devices and Diagnostics Industry Conference in San Francisco.